Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Stephan

Showing results (41-50 of 146) with videos related to

Pageof 15
Sort By:
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Deutsche Medizinische Wochenschrift (1946)|December 14, 2017
[Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital]Johanna Kessel, Barbara Dolff, Thomas Wichelhaus, et al.
HIV Medicine|October 30, 2024
Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort studyChristoph Stephan, Christoph D Spinner, Ansgar Rieke, et al.
Healthcare (Basel, Switzerland)|August 12, 2023
Interviews with HIV Experts for Development of a Mobile Health Application in HIV Care-A Qualitative StudyJannik Schaaf, Timm Weber, Michael von Wagner, et al.
Open Forum Infectious Diseases|September 17, 2024
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class ResistanceJacob Gerstenberg, Hartwig Klinker, Michael Baier, et al.
HIV Clinical Trials|August 9, 2013
Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controlsMarkus Bickel, Christin Lassmann, Imke Wieters, et al.
AIDS (London, England)|November 14, 2008
Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis countryChristoph Stephan, Timo Wolf, Udo Goetsch, et al.
Journal of the International AIDS Society|November 14, 2014
Proton 1H- and Phosphorus 31P-MR spectroscopy (MRS) in asymptomatic HIV-positive patientsGundolf Schuettfort, Elke Hattingen, Ulrich Pilatus, et al.
Plos One|March 5, 2013
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control studySonja M Bjerk, Jason V Baker, Sean Emery, et al.
Pageof 15

Showing results (41-50 of 146) with videos related to

Sort By:
Pageof 15
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Deutsche Medizinische Wochenschrift (1946)|December 14, 2017
[Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital]Johanna Kessel, Barbara Dolff, Thomas Wichelhaus, et al.
HIV Medicine|October 30, 2024
Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort studyChristoph Stephan, Christoph D Spinner, Ansgar Rieke, et al.
Healthcare (Basel, Switzerland)|August 12, 2023
Interviews with HIV Experts for Development of a Mobile Health Application in HIV Care-A Qualitative StudyJannik Schaaf, Timm Weber, Michael von Wagner, et al.
Open Forum Infectious Diseases|September 17, 2024
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class ResistanceJacob Gerstenberg, Hartwig Klinker, Michael Baier, et al.
HIV Clinical Trials|August 9, 2013
Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controlsMarkus Bickel, Christin Lassmann, Imke Wieters, et al.
AIDS (London, England)|November 14, 2008
Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis countryChristoph Stephan, Timo Wolf, Udo Goetsch, et al.
Journal of the International AIDS Society|November 14, 2014
Proton 1H- and Phosphorus 31P-MR spectroscopy (MRS) in asymptomatic HIV-positive patientsGundolf Schuettfort, Elke Hattingen, Ulrich Pilatus, et al.
Plos One|March 5, 2013
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control studySonja M Bjerk, Jason V Baker, Sean Emery, et al.
Pageof 15